Squamous-Cell Carcinoma of the Rectum: A Rare but Curable Tumor

Abstract

PURPOSE: This study was designed to evaluate one institution_s experience with treatment outcomes for rectal squamous-cell carcinoma. METHODS: Using our prospective Colorectal Database, we identified patients diagnosed with rectal squamous-cell carcinoma at our institution between 1983 and 2005. Pathology was rereviewed, tumor immunophenotype was compared to control cases of anal squamous-cell carcinoma and rectal adenocarcinoma, treatment modalities and outcomes were analyzed. RESULTS: Twelve patients were identified (10 females median age, 58 years). Median distal extent of tumors was 7 (range, 5-8) cm from the anal verge. Treatment included chemotherapy only (n = 1), chemoradiation only (n = 2), induction chemotherapy followed by chemoradiation and surgery (n = 2), chemoradiation followed by surgery (n = 5), and surgery followed by chemoradiation (n = 2). The chemotherapy regimen was 5-fluorouracil-based. Radiotherapy total dose was 50.4 Gy (1.8 Gy/day, daily  5) external iliac and inguinal nodes were not included in the radiation field. Complete clinical responders to chemoradiation (n = 2) received no further treatment. All seven partial responders underwent surgery; six had complete pathologic response; nodal status in two of six was unknown because they had local excision. Immunophenotypical analysis showed similar keratin expression profile between rectal squamous-cell carcinoma (n = 5) and rectal adenocarcinoma (n = 5), which is different from anal squamous-cell carcinoma (n = 10). All patients were alive without evidence of disease at follow-up (median follow-up, 2.6 (range, 0.5-16) years). CONCLUSIONS: Our data suggest that most patients treated with upfront chemoradiation therapy followed by surgery did well. Sphincter-preserving surgery is usually feasible. Clinical judgment of tumor response after chemoradiation is not completely reliable. Immunohistochemistry suggests a common cellular origin for rectal squamous-cell carcinoma and rectal adenocarcinoma, which is different from anal squamous-cell carcinoma.

Gemcitabine-based chemotherapy in colon squamous cell carcinoma: A case report and literature review

“…Generally, the treatment is based on that for adenocarcinomas, which is predominantly surgery combined with chemotherapy and radiotherapy. With the advances in chemotherapy and radiotherapy, the accuracy of determining stage and evaluating response, a multitude of recent studies utilizing various treatment regimens have been reported, which included 5-fluorouracil (5FU)/mitomycin C, 5FU, 5FU/cisplatin, capecitabine/cisplatin, capecitabine, raltitrexed/oxaliplatin and S-1 (10,11,.…”

Primary Squamous Cell Carcinoma of the Rectum Case Report with Literature Review

“…The chemoradiation was followed by surgical excision. When radiation therapy was added preoperatively, Nahas showed there was an increase in sphincter preserving procedures from 67% to 71% (15) . Guerra et al recommended that primary treatment should be CRT, with surgery reserved as a salvage option.…”

Successful Treatment of Squamous-Cell Rectal Cancer: А Case Report

“…Эта молекула будет экспрессироваться аденокарциномами и плоскокле-точным раком прямой кишки, но не анального канала [23]. Также это позволит исключить метастазы рака анального канала в параректальную клетчатку с инва-зией стенки прямой кишки.…”